PanCancer IO 360™ Panel


Facilitating rapid discovery and development of potentially predictive signatures with the most advanced view of immuno-oncology biology. 

The PanCancer IO 360 Gene Expression Panel is a unique 770 gene expression panel for research use only (RUO) that combines vital components involved in the complex interplay between the tumor, microenvironment and immune response in cancer allowing for a multifaceted characterization of disease biology and interrogation of mechanisms of immune evasion.

Developed specifically for translational research, this powerful new panel incorporates 47 potentially predictive Research Use Only (RUO) biological signatures including the 18-gene Tumor Inflammation Signature as recently described in JCI.

  • RUO panel for the research of possible predictive signatures for potential immunotherapy companion diagnostics
  • Allows for possible identification of responder/non-responder populations for immunotherapy research
  • Characterize disease biology
  • Interrogate mechanisms of immune evasion

Download Gene List:

Learn about our nCounter Analysis System and nSolver™ Analysis Software.



Tumor-Microenvironment-Immune Response

Tumor Immunogenicity Tumor Sensitivity to Immune Attack Inhibitory Immune Mechanisms Stromal Factors Inhibitory Metabolism Immune Activity Inhibitory Immune Signaling Immune Cell Population Abundance
Antigen processing machinery Apoptosis PDL1 gene expression Stromal tissue abundance Glycolytic Tumor Inflammation Signature Myeloid-derived Inflammatory signaling B-cells Mast Cells
Immunoproteasome Tumor proliferation IDO1 gene expression Endothelial cells Hypoxia Cytotoxicity Inflammatory chemokines CD45+ cells Neutrophils
MAGE genes Loss of JAK-STAT pathway gene expression B7-H3 gene expression     Interferon gamma signaling ARG1 gene expression CD8 T cells NK CD56dim cells
Loss of antigen presentation expression   TGF-β gene expression     Interferon signaling response NOS2 gene expression Cytotoxic cells NK cells
Loss of mismatch repair gene expression         Lymphoid compartment activity CTLA4 gene expression DC T-cells
          Myeloid compartment activity IL10 gene expression Exhausted CD8 Th1 cells (TBX21/bet expression)
          MHC class 2 antigen presentation PDL2 gene expression Macrophages Treg (FOXP3 expression)
            PD-1 gene expression    
            TIGIT gene expression    


Possible predictive signatures measuring IO biology trained through combination of domain knowledge, academic collaborations and mining of public and proprietary data.

13 Biological Pathways and Processes


Tumor Microenvironment Immune Response
Category/Gene Number Category/Gene Number Category/Gene Number
Release of Cancer Cell Antigens 74 Angiogenesis 40 Cancer Antigen Presentation 95
Cell Cycling and Proliferation 54 Extracellular Matrix Remodelling 43 T cell priming and Activation 151
Tumor Intrinsic Factors 156 Collagens 6 Immune Cells Localization to Tumors 293
Common Signaling Pathways 172 Metastasis 20 Recognition of Cancer Cells by T cells 103
    Killing of Cancers Cells 177
    Myeloid Cell Activity 262
    NK Cell Activity 28
    Immunometabolism 99


20 internal reference genes include overlapping genes from Hallmarks of Cancer PanCancer Collection for cross-panel comparisons.

Tumor Inflammation Signature1

The Tumor Inflammation Signature includes 18 functional genes known to be associated with response to PD-1/PD-L1 inhibitors pathway blockade.

Includes 4 Areas of Immune Biology: IFN-ү-responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance genes.


The tumor inflammation gene expression signature highlights the complex biology of the host immune microenvironment.

18-gene Tumor Inflammation Signature



View publication and video.

1. Ayers, Mark, et al. "IFN-y-related mRNA profile predicts clinical response to PD-1 blockade." The Journal of Clinical Investigation 127.8 (2017).

Ayers, Mark, et al. "IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade.The Journal of Clinical Investigation 127.8 (2017).

Danaher, Patrick, et al. "Gene expression markers of Tumor Infiltrating Leukocytes.Journal for immunotherapy of cancer 5.1 (2017): 18.

Satoh, Jun-ichi, and Hiroko Tabunoki. "A comprehensive profile of ChIP-Seq-based STAT1 target genes suggests the complexity of STAT1-mediated gene regulatory mechanisms.Gene regulation and systems biology 7 (2013): 41.

Becht, Etienne, et al. "Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression.Genome biology 17.1 (2016): 218.

Spranger, Stefani, Riyue Bao, and Thomas F. Gajewski. "Melanoma-intrinsic [beta]-catenin signalling prevents anti-tumour immunity.Nature 523.7559 (2015): 231.

Harris, B. H. L., et al. "Gene expression signatures as biomarkers of tumour hypoxia.Clinical Oncology 27.10 (2015): 547-560.

Manson, G., et al. "Biomarkers associated with checkpoint inhibitors.Annals of Oncology 27.7 (2016): 1199-1206.

Blank, Christian U., et al. "The “cancer immunogram”.Science 352.6286 (2016): 658-660.

For Research Use Only. Not for use in diagnostic procedures.